Tailoring adjuvant therapy for hormone receptor-positive breast cancer

Author(s):
Blok, E.J.
Published
2018
Publication type
Doctoral Thesis

Abstract

Although the survival of breast cancer has improved the past decades, there is still major over- and undertreatment for the majority of patients. The aim of this research was to identity the most optimal adjuvant endocrine therapy, with regard to the optimal duration of therapy and the selection of subgroups who require selected therapy.

Breast cancerAdjuvant_endocrine therapyAromatase inhibitorsTamoxifenTumour infiltrating lymphocytesEstrogen receptorGene expression profiling
Defense date
2018-05-31
Language
English
Supervisor(s)
Velde, C.J.H. van de
Advisor(s)
Kroep, J.R.; Kuppen, P.J.K.
Committee member(s)
Smit, V.T.H.B.M.; Linn, S.C.; Hoeven, J.J.M. van der
Qualification
Ph.D.
Degree granting institution
Heelkunde en Medische Oncologie, Medicine / Leiden University Medical Center (LUMC), Leiden University, Leiden
hdl
1887/63078
ISBN(s)
9789463323345

Funding

Sponsorship
Pfizer, Philips, Agendia, Chipsoft